LY 303496

Drug Profile

LY 303496

Latest Information Update: 23 Sep 1998

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 23 Sep 1998 No-Development-Reported for Thrombosis in USA (Unknown route)
  • 29 Mar 1996 A pharmacokinetic study in animals has been added to the pharmacokinetics section
  • 19 Mar 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top